Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

Arnold Bolomsky, Smriti Kanangat, Michele Ceribelli, Kristina Rinaldi, Lin Zhang, Elizabeth Hill, Jagan R. Muppidi, Craig J. Thomas, Ryan M. Young

Blood (2024) 144 (Supplement 1): 763.

https://doi.org/10.1182/blood-2024-208485

Published: 2024

Journal Articles

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7059.

https://doi.org/10.1182/blood-2024-201563

Published: 2024

Journal Articles

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure

Dickran Kazandjian, Christin DeStefano, Alexander Dew, Elizabeth Hill, Katie Thoren, Ola Landgren

Blood (2024) 144 (Supplement 1): 4669.

https://doi.org/10.1182/blood-2024-202196

Published: 2024

Journal Articles

Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias

Yong Zhang, David G. Coffey, Elizabeth Hill, Frank Cross, Jr., Reena Philip, Marc R. Theoret, Ola Landgren, Andrea C Baines, Dickran Kazandjian

Blood (2024) 144 (Supplement 1): 1907.

https://doi.org/10.1182/blood-2024-202574

Published: 2024

Journal Articles

Early Prognostic Biomarkers of Non-Relapse Mortality in Allogeneic Mismatched Unrelated Hematopoietic Cell Transplantation

Trent Wang, Anna Crawford, Denggang Fu, Elizabeth Hill, Antonio M. Jimenez Jimenez, Krishna V. Komanduri, Sophie Paczesny

Blood (2023) 142 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2023-180944

Published: 2023

Journal Articles

Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome

Alina Dulau-Florea, Raul C. Braylan, Yanna Ding, Nisha Patel, Katherine Calvo, Elizabeth Hill, Emma M. Groarke, Neal S. Young, Bhavisha A. Patel

Blood (2023) 142 (Supplement 1): 4681.

https://doi.org/10.1182/blood-2023-186736

Published: 2023

Journal Articles

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,068 Service Members Deployed to Either Europe or Iraq, with or without Reported Burn Pit and Toxic Smoke Exposure

Dickran Kazandjian, Christin DeStefano, Alexander Dew, Elizabeth Hill, Katie Thoren, Ola Landgren

Blood (2023) 142 (Supplement 1): 4770.

https://doi.org/10.1182/blood-2023-182169

Published: 2023

Journal Articles

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Blood (2023) 142 (Supplement 1): 337.

https://doi.org/10.1182/blood-2023-181811

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

Phase I Study of Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Brian T. Hess, Leandro Cerchietti, Lindsey Hendrickson, Elizabeth Hill, Anshu Giri, Shanta Salzer, Sarah Hogan, Lacey Finch, Robin Klingenberg, Fang Hu, Nina D. Wagner-Johnston

Blood (2021) 138 (Supplement 1): 3567.

https://doi.org/10.1182/blood-2021-145493

Published: 2021

Journal Articles

A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)

Eytan M. Stein, MD, Marina Konopleva, MD PhD, Raymond Gilmour, BSc, PhD, Anna M Szpurka, PhD, Elizabeth Hill, PhD, Renee Ward, MD PhD, Hagop M. Kantarjian, MD, Courtney D. Dinardo, MDMSc

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-134307

Published: 2020

Journal Articles

A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma

Emily Bryer, DO, Alexander Dew, DO, MS, Elizabeth Hill, MD, Elizabeth Gil Ramirez, MD, Candis Morrison, CNP, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Kevin Camphausen, MD, Jennifer Jones, MD PhD, Dickran Kazandjian, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136176

Published: 2020

Journal Articles

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Elizabeth Hill, MD, Neha Korde, MD, Candis Morrison, CNP, PhD, Alexander Dew, DO, MS, Ashley Carpenter, RN, Monica Epstein, RN, Crystal Lu, PharmD, BCOP, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-136182

Published: 2020

Journal Articles

Evaluation of Whole-Body MRI (WB-MRI) in Smoldering Multiple Myeloma (SMM)

Elizabeth Hill, MD, Baris Turkbey, MD, Evrim Turkbey, MD, Candis Morrison, CNP, PhD, Peter Choyke, MD, Esther Mena, MD, Liza Lindenberg, MD, Dickran Kazandjian, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-136185

Published: 2020

Journal Articles

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Blood (2020) 136 (Supplement 1): 43–45.

https://doi.org/10.1182/blood-2020-136148

Published: 2020

Journal Articles

Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

Elizabeth Hill, MD, Neha Korde, MD, Sham Mailankody, MBBS, Candis Morrison, CNP, PhD, Alexander Dew, DO, Jennifer Hsu Albert, RN, Katherine Graap, RN, Francesco Maura, MD, Ola Landgren, MD PhD, Dickran Kazandjian, MD

Blood (2019) 134 (Supplement_1): 1794.

https://doi.org/10.1182/blood-2019-126952

Published: 2019

Journal Articles

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

Blood (2018) 132 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2018-99-111712

Published: 2018

Journal Articles

The Utility Of 18 f-FDG PET/CT In Assessing Bone Marrow Involvement In Lymphoma

Chaitra S. Ujjani, MD, Elizabeth Hill, MD, Samer Nassif, MD, Hongkun Wang, PhD, Yiru Wang, BS, Metin Ozdemirli, MD, Giuseppe Esposito, MD, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 2981.

https://doi.org/10.1182/blood.V122.21.2981.2981

Published: 2013

Journal Articles

Risk and Outcome of Non-Hodgkin Lymphoma Among Hodgkin Lymphoma Survivors: Analysis From the Surveillance, Epidemiology and End Results (SEER) Registry.

Ana Xavier, MD, Kent Armerson, MS, Elizabeth Hill, PhD, Luciano J Costa, MD, PhD

Blood (2012) 120 (21): 2639.

https://doi.org/10.1182/blood.V120.21.2639.2639

Published: 2012

Journal Articles

Trends in Survival of Patients with Burkitt Lymphoma Diagnosed in the USA: An Analysis of 3691 Cases

Luciano J Costa, MD, PhD, Ana Xavier, MD, Amy Wahlquist, MS, Elizabeth Hill, PhD

Blood (2012) 120 (21): 761.

https://doi.org/10.1182/blood.V120.21.761.761

Published: 2012

NARROW

Proteogenomic Screens Identify Plasma Cell Specific Vulnerabilities to Halt Oncogenic Transcription in Multiple Myeloma

A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,589 Service Members Deployed to Either Iraq, Germany, or Not-Deployed Ex-US with or without Reported Burn Pit and Toxic Smoke Exposure

Novel T-Cell Receptor Signature Linked to Plasma Cell Dyscrasias

Early Prognostic Biomarkers of Non-Relapse Mortality in Allogeneic Mismatched Unrelated Hematopoietic Cell Transplantation

Clonal Bone Marrow Plasma Cells Are Common in Patients with Vexas Syndrome

Increased Risk of Monoclonal Gammopathy of Undetermined Significance in US Military Service Members: A Case-Control Study of 1,068 Service Members Deployed to Either Europe or Iraq, with or without Reported Burn Pit and Toxic Smoke Exposure

Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Phase I Study of Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)

A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma

The Role of 18 f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Evaluation of Whole-Body MRI (WB-MRI) in Smoldering Multiple Myeloma (SMM)

Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study

Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

The Utility Of 18 f-FDG PET/CT In Assessing Bone Marrow Involvement In Lymphoma

Risk and Outcome of Non-Hodgkin Lymphoma Among Hodgkin Lymphoma Survivors: Analysis From the Surveillance, Epidemiology and End Results (SEER) Registry.

Trends in Survival of Patients with Burkitt Lymphoma Diagnosed in the USA: An Analysis of 3691 Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only